Universitaetsklinikum Leipzig AöR

At Universitaetsklinikum Leipzig AöR, the Klinik und Poliklinik für Neurologie is involved in clinical research across nervous system diseases and related immune-mediated conditions. The studies focus on improving treatment options, understanding disease control, and evaluating longer-term safety for people living with complex neurological disorders.

• Multiple sclerosis and progressive supranuclear palsy, with trials aimed at reducing disease activity and slowing progression
• Chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis, studying new approaches to symptom control and relapse prevention
• Refractory focal epilepsy and stroke, with research designed to improve outcomes and support better neurologic recovery
• Glioblastoma and other brain tumors, exploring more effective treatment strategies and survival benefits

This portfolio reflects a strong emphasis on neuroinflammation, autoimmune neurology, and brain cancer, with the goal of advancing care for patients with difficult-to-treat neurological diseases.

The site supports a broad range of studies in immune system diseases and chronic inflammatory disorders, including conditions that affect the joints, connective tissue, and kidneys. These trials are generally aimed at testing new therapies, improving disease control, and assessing whether treatments can provide lasting benefit with acceptable safety.

• Systemic lupus erythematosus and lupus nephritis, focused on better control of active, refractory disease
• Psoriatic arthritis and axial spondyloarthritis, evaluating therapies intended to reduce inflammation and improve function
• Crohn’s disease and ulcerative colitis, studying options to induce and maintain remission
• Idiopathic inflammatory myopathies and primary membranous nephropathy, with research aimed at improving long-term disease management

This area highlights the center’s interest in autoimmune disease, inflammatory bowel disease, and rheumatologic disorders, supporting both symptom relief and deeper disease control.

Clinical trials at the Leipzig site cover a wide spectrum of neoplasms and blood cancers, from solid tumors to aggressive hematologic malignancies. The research is centered on testing new treatment combinations, refining post-surgical strategies, and improving survival in cancers with high unmet need.

• Breast cancer, including HER2-positive and hormone receptor-positive disease, with studies focused on improving early and advanced treatment outcomes
• Acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma, evaluating better disease control and transplant-related strategies
• Biliary tract cancer, hepatocellular carcinoma, and gastric cancer, with trials aimed at delaying recurrence and improving response
• Glioblastoma, melanoma, lymphoma, and ovarian cancer, exploring new options for difficult-to-treat or relapsed disease

The breadth of this portfolio shows a strong focus on cancer therapy, transplant-related hematology, and precision oncology, with an emphasis on better outcomes for both newly diagnosed and relapsed disease.

A substantial part of the research activity addresses digestive system diseases, liver diseases, and metabolic conditions. These studies aim to improve treatment for chronic liver injury, inflammatory bowel disease, and related complications, while also exploring ways to prevent progression and hospitalization.

• Alcohol-related liver disease, acute-on-chronic liver failure, and cirrhosis, with trials focused on safety, survival, and disease stabilization
• Non-alcoholic steatohepatitis and obesity, studying whether treatment can improve liver health and reduce future risk
• Primary sclerosing cholangitis and chronic hepatitis B, evaluating new approaches to long-term disease control
• Crohn’s disease, ulcerative colitis, and coeliac disease, with work aimed at improving remission and symptom management

Research in this area combines hepatology, gastroenterology, and metabolic medicine, reflecting the site’s interest in chronic diseases that often require ongoing multidisciplinary care.

The clinical trial program also includes important work in cardiovascular diseases, kidney disorders, and peripheral vascular disease. The studies are designed to improve blood pressure control, protect organ function, and reduce serious events such as heart failure, kidney injury, and vascular complications.

• Heart failure and hypertension, with trials testing better ways to lower risk and improve cardiovascular outcomes
• Peripheral arterial disease and chronic limb-threatening ischemia, focused on improving vascular procedures and patient safety
• Primary IgA nephropathy, Alport syndrome, and other kidney diseases, evaluating treatments that may slow progression
• Acute pulmonary embolism and atherosclerotic cardiovascular disease, studying strategies to reduce complications and improve recovery

This research area combines cardiology, nephrology, and vascular medicine, with a clear focus on prevention, organ protection, and better long-term outcomes.

Beyond the major disease areas, the site contributes to studies in congenital, hereditary, and neonatal diseases as well as other specialized conditions. These trials often seek to address unmet needs in children, young adults, and patients with rare or complex disorders.

• Extremely premature infants and chronic lung disease, with research aimed at improving survival and early health outcomes
• X-linked hypohidrotic ectodermal dysplasia and Alport syndrome, exploring targeted treatment options for rare inherited conditions
• Classical homocystinuria and PIK3CA-related overgrowth spectrum, focusing on better disease understanding and supportive care
• Analytical and diagnostic techniques, supporting more precise assessment of disease activity and treatment response

This mix of studies shows a commitment to rare disease research, pediatric medicine, and diagnostic innovation, helping expand options where standard treatments are limited.